Neurophth Announces IND Approval by the NMPA for Leber Hereditary Optic Neuropathy Gene Therapy
News provided by
Share this article
Share this article
WUHAN and SUZHOU, China, April 1, 2021 /PRNewswire/ Neurophth Biotechnology Ltd., a fully-integrated genomic medicines company developing adeno-associated viral (AAV)-delivered gene therapies for the treatment of ocular diseases, recently announced the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved the Company s Investigational New Drug (IND) application of NR082 (recombinant adeno-associated virus serotype 2 carrying
ND4 gene; rAAV2-
ND4 mutations.
It marks the first AAV2 gene therapy IND application approval in China. Previously, the company announced NR082 has granted orphan drug designation by the US FDA in September 2020
Share this article
Share this article
OTTAWA, ON, April 1, 2021 /CNW/ - Canada s universal, publicly funded health care system is a source of pride for Canadians. The Government of Canada is working closely with provincial and territorial governments to strengthen health care and adapt the system to the challenges of delivering health care during the COVID-19 pandemic.
Today, the Honourable Patty Hajdu, Minister of Health, announced the signature of a bilateral agreement with Saskatchewan to expand virtual health care services for its residents. Under the agreement, the province will invest federal funding based on agreed-upon pan-Canadian priorities for accelerating virtual health care services during the pandemic.
Empirical Spine Receives FDA Breakthrough Device Designation for the LimiFlex Device Targeting Degenerative Spondylolisthesis
The Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.
News provided by
Share this article
Share this article
SAN CARLOS, Calif., April 1, 2021 /PRNewswire/ Empirical Spine, Inc., a company developing advanced solutions for the surgical treatment of spinal disorders, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) for its LimiFlex™ Paraspinous Tension Band.
Empirical Spine
Share this article
Share this article
KNOXVILLE, Tenn., April 1, 2021 /PRNewswire/ Pilot Company, one of the leading suppliers of fuel and the largest network of travel centers in North America, announced today it will offer a one-time, $75 incentive to team members who choose to get the COVID-19 vaccine. The incentive will be available to all Pilot Company hourly team members, professional drivers and general managers in the United States and Canada.
Pilot Company team member stocks and cleans the coffee station at the Flying J Travel Center on Watt Road in Knoxville, Tennessee on June 18, 2020. Our team members and drivers have been on the front lines keeping our travel centers going and the economy moving since the start of the pandemic, said Shameek Konar, Pilot Company CEO. We are incredibly proud of their dedication to serving our guests and supplying fuel across North America. Now, as the COVID-19 vaccine becomes more available, we hope to make it easier for our team
Darlene Soave Joins Cell Source s Board of Directors
News provided by
Share this article
Share this article
NEW YORK, April 1, 2021 /PRNewswire/ Cell Source, Inc. (OTC: CLCS) ( Cell Source or the Company ), is the world leader in Veto Cell based innovative immunotherapy and today announced that Darlene Soave has been appointed to the Company s Board of Directors, effective March 25, 2021. Veto Cells, in different mouse models, have shown that they have the potential to safely facilitate mismatched donor stem cell (e.g. bone marrow) transplants and organ transplants. In addition, in preclinical trials, Veto Cells have shown that they can durably treat malignant and non-malignant blood diseases through active immune response management.